PharmiNews

The Directory of Pharma Companies and News

Abbvie

Abbvie logo
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Category: Pharmaco
Category: Pharmaco

Abbvie News

DateNews
2017-04-21AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference
2017-04-21Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved...
2017-04-20AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SV...
2017-04-19AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for t...
2017-04-07AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Mens...
2017-04-06AbbVie to Host First-Quarter Earnings Conference Call
2017-04-05AbbVie Celebrates 25th Year of its CF Scholarship and is Now Accepting Applications from Students with Cystic Fibrosis
2017-04-04AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Ho...
2017-03-30U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing ...
2017-03-28AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Resea...
2016-03-30AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Inv...
2016-03-08AbbVie to Present at Barclays Global Healthcare Conference
2016-03-07AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
2016-03-04IMBRUVICA® (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia
2016-03-02AbbVie Announces New Dermatology Research from More Than 35 Presentations on HUMIRA® (Adalimumab), Long-Term and Real-Wo...
2016-02-29AbbVie to Present at Cowen and Company 36th Annual Health Care Conference
2016-02-26AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid L...
2016-02-26ABBVIE RECEIVES CHMP POSITIVE OPINION FOR VIEKIRAX® (OMBITASVIR/PARITAPREVIR/RITONAVIR TABLETS) + EXVIERA® (DASABUVIR TA...
2016-02-11AbbVie Launches Scholarship to Support Students Living with Rheumatologic Diseases
2016-02-10AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometrios...
2016-01-29AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results
2016-01-28AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
2016-01-27Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Unt...
2016-01-21MD Anderson, AbbVie Connect to Advance Cancer Immunotherapy
2016-01-20AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment o...
2016-01-12U.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chroni...
2016-01-11AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
2016-01-08AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JA...
2016-01-07FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, r...
2016-01-07AbbVie to Host Fourth-Quarter and Full-Year 2015 Earnings Conference Call
2015-12-16AbbVie to Present at the 34th Annual J.P. Morgan Healthcare Conference
2015-12-07IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relaps...
2015-12-07Combination Ibrutinib (IMBRUVICA®) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymph...
2015-12-06AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Ch...
2015-12-06AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Delet...
2015-12-06Ibrutinib (IMBRUVICA®) Improves Survival in Treatment-Naive Chronic Lymphocytic Leukemia Patients in the Phase 3 RESONAT...
2015-12-06Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma
2015-12-04AbbVie Launches Crohn's & Colitis Scholarship to Support Students Living with Inflammatory Bowel Disease
2015-12-02AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, parita...
2015-11-16AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen ...
2015-11-14AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients w...
2015-11-13AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
2015-11-05AbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts...
2015-11-05AbbVie to Present at Jefferies Autumn 2015 Global Healthcare Conference in London
2015-11-03AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with M...
2015-11-02AbbVie to Present at Credit Suisse 24th Annual Healthcare Conference
2015-10-30AbbVie Reports Third-Quarter 2015 Financial Results
2015-10-30AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance
2015-10-28IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent
2015-10-22AbbVie Updates U.S. Labels for VIEKIRA PAK® and TECHNIVIE™
2015-10-08Real Stories, Real Voices Break the Silence Around a Painful, Chronic Skin Disease
2015-10-06AbbVie to Host Third-Quarter Earnings Conference Call
2015-10-05AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology C...
2015-10-01AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavi...
2015-09-28AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype ...
2015-09-25AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End
2015-09-25AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis
2015-09-16AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids
2015-09-14AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chroni...
2015-09-11Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir t...
2015-09-10AbbVie to Present at 2015 Morgan Stanley Global Healthcare Conference
2015-09-10AbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe ...
2015-09-09Cast Your Vote for the 2015 Thriving Undergraduate and Graduate Scholars to Help Grant Two $20,500 AbbVie Scholarships t...
2015-08-12Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Pr...
2015-07-30HUMIRA® (Adalimumab) Approved by European Commission for Moderate to Severe Hidradenitis Suppurativa (HS)
2015-07-24AbbVie Reports Second-Quarter 2015 Financial Results
2015-07-24TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Inter...
2015-07-17C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclea...
2015-07-10IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe
2015-07-02AbbVie to Host Second-Quarter Earnings Conference Call
2015-06-29AbbVie Expands Medical Device Facility in Sligo, Ireland With €40 Million Investment
2015-06-26AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Adult Patients with Active Moderate to Severe Hidr...
2015-06-24AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
2015-06-18AbbVie Declares Quarterly Dividend
2015-06-12Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/...
2015-06-12AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Diseas...
2015-06-09AbbVie Presents Phase 3 Data Demonstrating Efficacy and Safety of HUMIRA® (adalimumab) in Children and Adolescents with ...
2015-06-08AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally
2015-06-08AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annua...
2015-06-05AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference
2015-06-04AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015
2015-06-04Ibrutinib (IMBRUVICA®) Improved Survival for Treatment-Naive Chronic Lymphocytic Leukemia Patients in Phase III RESONATE...
2015-06-01AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Ca...
2015-06-01AbbVie to Present at Jefferies 2015 Healthcare Conference
2015-05-31AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at...
2015-05-26AbbVie Completes Acquisition of Pharmacyclics
2015-05-26AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis
2015-05-22AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics
2015-05-21AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics
2015-05-15AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Inve...
2015-05-13AbbVie to Present at UBS Global Healthcare Conference
2015-05-12AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015
2015-05-11AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Societ...
2015-05-06Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocy...
2015-05-06AbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference
2015-05-05AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infect...
2015-04-29AbbVie to Present at Deutsche Bank 40th Annual Health Care Conference
2015-04-25AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with ...
2015-04-23AbbVie Reports First-Quarter 2015 Financial Results
2015-04-23U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Ge...
2015-04-17AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
2015-04-15AbbVie to Host First-Quarter Earnings Conference Call
2015-04-15AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan
2015-04-08AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015
2015-04-01AbbVie CF Scholarship Application for Students with Cystic Fibrosis Now Available for 2015-2016 Academic School Year
2015-04-01AbbVie's HUMIRA® (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic Plaq...
2015-03-19AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy
2015-03-17AbbVie's Dermatology Leadership Showcased with HUMIRA® (adalimumab) Data at American Academy of Dermatology 2015 Annual ...
2015-03-06AbbVie to Present at Barclays Global Health Care Conference
2015-03-04AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematologica...
2015-02-27AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic Plaqu...
2015-02-26AbbVie Launches SigueElGuion.com to Educate Spanish-Speaking Americans about Hypothyroidism and the Importance of Dialog...
2015-02-26AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual...
2015-02-25AbbVie to Present at Cowen 35th Annual Health Care Conference
2015-02-23Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic ...
-0001-11-30AbbVie Launches Good Morning Hypothyroidism to Help Hypothyroid Patients Manage their Life-Long Condition through Educat...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.